In the AFFIRM-AHF trial of 1,108 patients stabilised after acute heart failure with iron deficiency, intravenous ferric carboxymaltose lowered total heart failure hospitalisations against placebo (rate ratio 0.74) without changing cardiovascular death.
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
created page created as 'Ferric carboxymaltose' with aliases FCM, Injectafer, Ferinject, iron(III) carboxymaltose · 2026-09-27 12:04 · somebody
kind set kind set to mineral: palette r2 · 2026-09-27 12:04 · somebody
identity withheld identity not published: PubChem gave no record that proves it is this substance · 2026-09-27 12:04 · somebody
fact added summary: In the AFFIRM-AHF trial of 1,108 patients stabilised after acute heart failure with iron deficiency, intravenous ferric · 2026-09-27 12:04 · somebody
fact added summary: In two randomized trials in iron-deficiency anemia, hypophosphatemia followed ferric carboxymaltose in about 74-75% of p · 2026-09-27 12:04 · somebody
citation added pmid 32016310 cited as established: Ferric carboxymaltose causes far more hypophosphatemia than iron isomaltoside (two RCTs) · 2026-09-27 12:04 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.